English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Purpose: Histopathological examination is sufficient for diagnosis of many melanocytic neoplasms, however, diagnostic discordance is common between dermatopathologists. A timely and confident diagnosis is optimal, especially in cases where both benign and malignant melanocytic neoplasms are considered in the differential diagnosis as treatment plans diverge significantly. A 35-gene expression profile (GEP) test that classifies melanocytic lesions into categories (benign, intermediate-risk and malignant), has reported accuracy metrics of 99.1% sensitivity, 94.3% specificity, 93.6% positive predictive value and 99.2% negative predictive value in a validation cohort of 503 samples. The clinical utility of the 35-GEP is described. Methods: Dermatopathologists (n=6) and dermatologists (n=14) were queried regarding diagnostic challenges and patient management strategies in 60 difficult-to-diagnose melanocytic neoplasms. Participants reviewed each lesion twice, once without the 35-GEP result and once with. Responses were evaluated for consistent trends in the utilization of the 35-GEP test result. Results: Dermatopathologists utilized the 35-GEP result to refine their diagnoses in lesions receiving a benign vs. malignant 35-GEP result (82.3% diagnostic downgrade vs. 94.9% diagnostic upgrade, respectively). Overall, diagnostic confidence was increased (51%), while additional work-up requests were decreased in cases with benign 35-GEP (72.1%) and increased with malignant 35-GEP (45.6%) results. Dermatologists utilized the 35-GEP result to gauge overall prognosis which was increased in 76.2% of responses for cases with a benign 35-GEP result and decreased in 94.2% of cases with malignant 35-GEP result. Case difficulty was increased in 54% of responses with a malignant 35-GEP result and decreased in 25% if a benign 35-GEP result was provided. Alterations in office visit frequency (25.9% increase in benign vs. 95.2% increase in malignant 35-GEP result) and re-excisions (76.7% decrease in re-excision in benign vs. 44.5% increase in re-excision in malignant 35-GEP result) were also influenced by the 35-GEP result. Conclusions: The diagnosis of challenging melanocytic neoplasms and subsequent clinical management decisions are influenced by 35-GEP results in a manner that agrees with the test result. The utility of the test provides the opportunity to improve patient care.

skin

A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists